What is Sensimed?
Based in Lausanne, Switzerland, Sensimed S.A. occupies a unique position at the intersection of medical device innovation and digital health. The company is best known for the SENSIMED Triggerfish, the first smart contact lens designed to provide a comprehensive 24-hour profile of eye health. By offering continuous monitoring, the technology provides healthcare professionals with actionable data that static measurements often miss, thereby improving clinical outcomes for glaucoma patients. This focus on high-precision diagnostics has established Sensimed as a key player in the global ophthalmology market, catering to specialized eye care organizations and clinical practitioners seeking to modernize patient management protocols.
How much funding has Sensimed raised?
Sensimed has raised a total of $24.8M across 2 funding rounds:
Series A
$6.9M
Series C
$17.9M
Series A (2007): $6.9M with participation from Wellington Partners, BlueOcean Ventures, and VINCI CAPITAL
Series C (2012): $17.9M led by Sandoz Fmaily Foundation, Vinci Capital/Renaissance PME, Wellington Partners, ELM Development, and Agate Medical Investments
Key Investors in Sensimed
Wellington Partners
A leading European venture capital firm that invests in early- and growth-stage life science companies, focusing on medical devices and digital health.
Agate Medical Investments
A venture capital firm specializing in providing growth capital to mature MedTech companies, with a focus on later-stage medical devices and digital health technologies.
BlueOcean Ventures
An investment company focused on early-stage medical device and life science companies, providing strategic guidance and financial backing to innovative ventures.
What's next for Sensimed?
Following its major enterprise-level funding, Sensimed is well-positioned to scale its commercial operations and expand the clinical adoption of its smart lens technology. The strategic roadmap likely involves deepening market penetration in key European and international territories while continuing to refine the data analytics capabilities of the Triggerfish system. As the company transitions from a development-focused entity to a mature commercial enterprise, the focus will shift toward integrating its diagnostic insights into broader electronic health record systems, further cementing its role as an essential partner in the evolving landscape of chronic disease management and personalized medicine.
See full Sensimed company page